VIA Medical neonatal blood gas and chemistry monitor system launch expected in spring of 1998.
This article was originally published in The Gray Sheet
Executive Summary
VIA MEDICAL NEONATAL BLOOD GAS AND CHEMISTRY MONITOR LAUNCH NEXT SPRING for use in neonatal intensive care units is anticipated by the company. A similar adult version of the portable system, also intended for near-real-time, point-of-care bedside blood gas and chemistry monitoring, commenced U.S. shipments Dec. 1 at a list price of $7,995, the firm says. Disposable sensors used with the device, which last up to three days, list for $165 each. The neonatal version of the system will be priced at a slight premium to the adult version but final pricing has not yet been set, according to the company.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.